Long-term evolution and predictive factors of mild inflammatory bowel disease

被引:11
|
作者
Reenaers, C. [1 ]
Pirard, C. [1 ]
Vankemseke, C. [1 ]
Latour, P. [1 ]
Belaiche, J. [1 ]
Louis, E. [1 ]
机构
[1] Univ Hosp Liege, Dept Gastroenterol, Liege, Belgium
关键词
Benign evolution; mild IBD; complication; predictive factor; CROHNS-DISEASE; ULCERATIVE-COLITIS; COLORECTAL-CANCER; CLINICAL-COURSE; RISK; CLASSIFICATION; INFECTIONS; MORTALITY; COLECTOMY; BEHAVIOR;
D O I
10.3109/00365521.2015.1128965
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Crohn's disease (CD) and ulcerative colitis (UC) are potentially progressive diseases. Few data are available on the prevalence and the factors associated with mild inflammatory bowel diseases (IBD). Aim Our aim was to assess the natural history of mild CD and mild UC and to identify predictive factors of mild evolution over the long term. Methods Retrospective study of IBD patients registered in the database of the university hospital CHU of Liege, Belgium. Mild CD was defined as an inflammatory luminal disease (no stricture, abdominal or perianal fistulae) requiring no immunomodulator (IM), anti-TNF and no surgery. Mild UC was defined as no requirement for IM, anti-TNF and no colectomy. Results Four hundred and seventy-three CD and 189 UC were included (median follow-up: 13 and 11 years respectively). At 1 year, 147 patients had mild CD. At 5 years and the maximum follow-up, 56% and 13% patients still had mild CD, respectively. At 1 year, 142 patients had mild UC. At 5 years and the maximum follow-up, 72% and 44% still had a mild UC, respectively. Factors associated with long-term mild CD and UC were older age at diagnosis and absence of corticosteroids in the first year. In UC proctitis location was associated with mild UC. Conclusions In this cohort, 90% of CD patients and 3/4 of UC with mild disease at 1 year lost their mild disease status over time. An old age at diagnosis was predictive of the persistence of a mild CD and UC.
引用
收藏
页码:712 / 719
页数:8
相关论文
共 50 条
  • [11] ANTIMETABOLITES IN INFLAMMATORY BOWEL-DISEASE - LONG-TERM EXPERIENCE
    KORELITZ, BI
    MOUNT SINAI JOURNAL OF MEDICINE, 1990, 57 (05): : 297 - 304
  • [12] Long-Term Impact of Clostridium difficile On Inflammatory Bowel Disease
    Chiplunker, Adeeti
    Ananthakrishnan, Ashwin N.
    Beaulieu, Dawn B.
    Naik, Amar S.
    Zadvornova, Yelena
    Skaros, Susan
    Johnson, Kathryn
    Perera, Lilani P.
    Binion, David G.
    Issa, Mazen
    GASTROENTEROLOGY, 2009, 136 (05) : A199 - A199
  • [13] Long-term outcome of inflammatory bowel disease—Unclassified in children
    Paul S.P.
    Sandhu B.K.
    Indian Pediatrics, 2017, 54 (9) : 742 - 745
  • [14] Inflammatory bowel disease: Short- and long-term treatments
    Bickston, SJ
    Cominelli, F
    DM DISEASE-A-MONTH, 1998, 44 (04): : 144 - 172
  • [15] Long-Term Outcomes of Thalidomide in Refractory Inflammatory Bowel Disease
    Yoon, Jessica
    Gerich, Mark
    Targan, Stephan
    Ippoliti, Andrew
    Vasiliauskas, Eric
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S694 - S695
  • [16] Long-term Outcome of Inflammatory Bowel Disease Unclassified in Children
    Paul, Siba Prosad
    Sandhu, Bhupinder Kaur
    INDIAN PEDIATRICS, 2017, 54 (09) : 742 - 745
  • [17] Long-Term Scheduled Therapy with Infliximab in Inflammatory Bowel Disease
    Armuzzi, Alessandro
    De Vincentis, Fabio
    Marzo, Manuela
    Mocci, Giammarco
    Felice, Carla
    Fedeli, Paolo
    De Vitis, Italo
    Papa, Alfredo
    Gasbarrini, Antonio
    Guidi, Luisa
    GASTROENTEROLOGY, 2009, 136 (05) : A663 - A663
  • [18] Long-term management of anemia in chronic inflammatory bowel disease
    Mickisch, O
    Baniewicz, W
    Lutz-Vorderbrügge, A
    Schreiber, S
    Küppers, B
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2002, 40 (04): : 241 - 248
  • [19] Long-term scheduled therapy with infliximab in inflammatory bowel disease
    Armuzzi, A.
    De Vincentis, F.
    Marzo, M.
    De Pascalis, B.
    Roberto, I.
    Mocci, G.
    Fiore, F.
    Leso, V.
    Fedeli, P.
    Papa, A.
    De Vitis, I.
    Melina, D.
    Fedeli, G.
    Gasbarrini, A.
    Guidi, L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2009, 13 : 84 - 84
  • [20] Long-Term Efficacy of Vedolizumab in Pediatric Inflammatory Bowel Disease
    Sarles, Harry E., Jr.
    Whitney, Annette E.
    Kuten, Samantha A.
    Van Anglen, Lucinda J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S643 - S644